Alnylam Pharmaceuticals: RBC cuts target price to $345 from $350
ALNY•RBC cut its target price for Alnylam Pharmaceuticals to $345 from $350.
Related News
EasyJet reportedly sees Apollo takeover on track for completion next year
APO•
Entegris coverage initiated at Stifel with buy rating; target price $200
ENTG•
X4 Pharmaceuticals secures up to $150 million senior debt facility with K2 HealthVentures
XFOR•
Senseonics Holdings: Stifel raises target price to $9 from $8
SENS•
Glaukos signs exclusive license deal with RevOpsis for retinal biologic RO-104
GKOS•